## Autologous CAR-T Product Reporting Options

<table>
<thead>
<tr>
<th>Revenue Code</th>
<th>Notes</th>
<th>HCPCS Code</th>
<th>HCPCS Product Code Description</th>
<th>Special Instructions for Clinical Trials and Expanded Access Cases</th>
<th>Payment Implications</th>
<th>Revenue Code</th>
<th>Notes</th>
<th>HCPCS Code</th>
<th>HCPCS Product Code Description</th>
<th>Payment Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>02064</td>
<td></td>
<td>Q2061</td>
<td>Autologous clinacanche, up to 200 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td>For CAR-T cases where the hospital does not incur a cost for the product itself, Medicare will pay a reduced amount of MS DIRG 018.</td>
<td>Depend on the Medicar Program</td>
<td>02064</td>
<td></td>
<td>Q2061</td>
<td>Autologous clinacanche, up to 200 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td>Medicare pays a reduced amount of MS DIRG 018.</td>
</tr>
<tr>
<td>02065</td>
<td></td>
<td>Q2062</td>
<td>Trigeminal hypovascular car-positive viable t cell, including leukapheresis and dose preparation procedures, per therapeutic dose</td>
<td></td>
<td></td>
<td>02065</td>
<td></td>
<td>Q2062</td>
<td>Trigeminal hypovascular car-positive viable t cell, including leukapheresis and dose preparation procedures, per therapeutic dose</td>
<td>Medicare pays a reduced amount of MS DIRG 018.</td>
</tr>
<tr>
<td>02066</td>
<td></td>
<td>Q2063</td>
<td>Autologous monarfin, up to 200 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td></td>
<td></td>
<td>02066</td>
<td></td>
<td>Q2063</td>
<td>Autologous monarfin, up to 200 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td>Medicare pays a reduced amount of MS DIRG 018.</td>
</tr>
<tr>
<td>02067</td>
<td></td>
<td>Q2064</td>
<td>Benyclopin clinacanche, up to 480 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td></td>
<td></td>
<td>02067</td>
<td></td>
<td>Q2064</td>
<td>Benyclopin clinacanche, up to 480 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td>Medicare pays a reduced amount of MS DIRG 018.</td>
</tr>
<tr>
<td>02068</td>
<td></td>
<td>Q2065</td>
<td>Autologous autacex, up to 500 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td></td>
<td></td>
<td>02068</td>
<td></td>
<td>Q2065</td>
<td>Autologous autacex, up to 500 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td>Medicare pays a reduced amount of MS DIRG 018.</td>
</tr>
<tr>
<td>02069</td>
<td></td>
<td>Q2066</td>
<td>Chloroquine autacex, up to 500 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td></td>
<td></td>
<td>02069</td>
<td></td>
<td>Q2066</td>
<td>Chloroquine autacex, up to 500 million autologous anti-CD19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.</td>
<td>Medicare pays a reduced amount of MS DIRG 018.</td>
</tr>
</tbody>
</table>

### Payment Implications

- **MS DIRG 018**: MS DIRG 018 is provided for inclusion in costs for the first case where the hospital begins to perform clinical trials in or after the period reported by the facility. Product charges are used to determine payments for the first case setting.
- **Outpatient Claim - Facility Reporting**: For clinical trial cases where the CAR-T product is under investigation, the provider may enter Billing Note NTE02 "CAR-T Trial Priced Out" on the electronic claim or put "Expand Acc Use " in the remarks field on a paper claim (Form Locator 80). For clinical trial cases where the CAR-T product is under investigation, report diagnosis code 20 A and condition code 10 to receive the reduced MS DIRG 018 payment on the claim (Form Locator 80).
- **Revenue Code 0891 (an extension of pharmacy 025x or 063x)** was created by the National Uniform Billing Committee (NUBC) to support reporting of the new codes per the HIPAA transaction code set regulation. Additionally, providers should review the instructions released in the Medicare Special Edition article SE 19009 published May 28, 2019 updates information in the April 2019 OPPS Update and Oct 2019 OPPS Update. Value code 86 may be used to report product acquisition cost if requested or allowed.

### Outpatient Claim - Facility Reporting

- **Condition code 90 on the claim to receive the reduced MS DIRG 018 payment**: Inpatient providers should report an appropriate charge as this will impact future MS-DRG 018 rate-setting.
- **Check with your payer**: The charge for the procedure is reported on the claim with the appropriate HCPCS code for the product NDC until a HCPCS code is released; also check with your payer.

### Inpatient Claim - Facility Reporting

- **MS DIRG 018**: MS DIRG 018 is provided for inclusion in costs for the first case where the hospital begins to perform clinical trials in or after the period reported by the facility. Product charges are used to determine payments for the first case setting.
- **Outpatient Claim - Facility Reporting**: For clinical trial cases where the CAR-T product is under investigation, the provider may enter Billing Note NTE02 "CAR-T Trial Priced Out" on the electronic claim or put "Expand Acc Use " in the remarks field on a paper claim (Form Locator 80). For clinical trial cases where the CAR-T product is under investigation, report diagnosis code 20 A and condition code 10 to receive the reduced MS DIRG 018 payment on the claim (Form Locator 80).
- **Revenue Code 0891 (an extension of pharmacy 025x or 063x)** was created by the National Uniform Billing Committee (NUBC) to support reporting of the new codes per the HIPAA transaction code set regulation. Additionally, providers should review the instructions released in the Medicare Special Edition article SE 19009 published May 28, 2019 updates information in the April 2019 OPPS Update and Oct 2019 OPPS Update. Value code 86 may be used to report product acquisition cost if requested or allowed.

---

**Autologous CAR-T Therapy Services - Updated as of April 1, 2024**

- **HCPCS code 0891** - Special Therapeutic Drug or Therapy
- **HCPCS code 025x** - Medicare
- **HCPCS code 063x** - Medicaid
- **HCPCS code 0892** - Special Therapeutic Drug or Therapy
- **HCPCS code 025x** - Medicare
- **HCPCS code 063x** - Medicaid
- **HCPCS code 0893** - Special Therapeutic Drug or Therapy
- **HCPCS code 025x** - Medicare
- **HCPCS code 063x** - Medicaid
- **HCPCS code 0894** - Special Therapeutic Drug or Therapy
- **HCPCS code 025x** - Medicare
- **HCPCS code 063x** - Medicaid
- **HCPCS code 0895** - Special Therapeutic Drug or Therapy
- **HCPCS code 025x** - Medicare
- **HCPCS code 063x** - Medicaid

**Revenue Code 0891 (an extension of pharmacy 025x or 063x)** was created by the National Uniform Billing Committee (NUBC) to support reporting of the new codes per the HIPAA transaction code set regulation. Additionally, providers should review the instructions released in the Medicare Special Edition article SE 19009 published May 28, 2019 updates information in the April 2019 OPPS Update and Oct 2019 OPPS Update. Value code 86 may be used to report product acquisition cost if requested or allowed.